A Study of LY3200882 in Participants With Solid Tumors

Launched by ELI LILLY AND COMPANY · Oct 17, 2016

Keywords

ClinConnect Summary

This clinical trial is studying a new drug called LY3200882 to see how safe it is for people with solid tumors, which are tumors that can form in various parts of the body, excluding blood cancers. The trial is currently active but not recruiting new participants. It is open to adults aged 65 to 74 who have been diagnosed with cancer and have enough healthy organ function to participate. To be eligible, participants should be able to perform daily activities on their own and must be able to swallow capsules and tablets.

If someone joins this study, they can expect to take the study drug and be closely monitored by healthcare professionals for any side effects or reactions. The goal is to ensure the safety of the drug for future use in treating solid tumors. It’s important to know that individuals with serious heart problems or other significant health issues, as well as those with acute leukemia, cannot participate in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The participant must have histological or cytological evidence of cancer.
• • Have adequate organ function.
• • Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
• • Are able to swallow capsules and tablets.
• Exclusion Criteria:
• • Have moderate or severe cardiovascular disease.
• • Have a serious concomitant systemic disorder.
• • Have acute leukemia.